Novartis Ag

University of Pennsylvania

Marengo Therapeutics, Inc.

University of Pittsburgh

The University of Chicago

Irm LLC

Engels, Boris

Andreas Loew

Jennifer Brogdon

Carl H June

Li Zhou

Saar Gill

Ming Lei

Michael C Milone

Qilong Wu

Huijuan Song

Joan Mannick

Stuart Licht

Daniel J Powell

Yangbing Zhao

Brian Edward Vash

John Scholler

Boris Engels

Marco Ruella

David Jonathan Glass

Marcela V Maus

Leon Murphy

Jonathan Hsu

Stephanie J Maiocco

Seng-Lai Tan

David Jenkins

Dilini Charmain Gunasekera

Sangeetha Sagar Palakurthi

Gregory Beatty

Neeraja Idamakanti

John Hastewell

Yongqiang Wang

David L Porter

Shari Lynn Caplan

Lu Huang

Hideho Okada

Jennifer Bordeaux

Brian R Boettcher

Brian Walter Granda

Jiquan Zhang

Norio Hamamatsu

Jimin Zhang

Stephen Craig Weldon

Douglas S Daniels

Na Li

Naveen Kumar Dakappagari

Ju Young Kim

Thai Tran

Saad Kenderian

Hans Bitter

Laura Alexandra Johnson

Elena Orlando

Steven Highfill

Bernhard Hubert Geierstanger

Michael D Kalos

Barbara Brannetti

Jan Weiler

Madan Katragadda

Susan E Cellitti

Enxiu Wang

William Raj Sellers

Nidhi Malhotra

Shohei Koide

Seth Alexander Ettenberg

Carla Guimaraes

Feng Cong

Akiko Koide

Karen Vincent

Melissa Ramones

Peter Marek

Gurkan Guntas

Ilaria Lamberto

John Leonard Herrmann

Anette Huebner

John Bernard Wojcik

Ryan Nicholas Gilbreth

Bernhard Hubert Geierstranger

Jennifer Mary Bordeaux

Susan E Litti

Berhard Hubert Geierstanger

Multispecific, e.g., bispecific, antibody molecules that include a kappa light chain polypeptide and one lambda light chain polypeptide, and methods of making and using the multispecific antibody molecules, are disclosed.

Multispecific antibody molecules comprising lambda and kappa light chains

Antibody molecules that specifically bind to NKp30 are disclosed. The anti-NKp30 antibody molecules can be used to treat, prevent and/or diagnose cancerous, autoimmune or infectious conditions and disorders.

Antibody molecules that bind to NKP30 and uses thereof

Multifunctional molecules that include i) an antigen binding domain that binds to a T cell receptor beta chain constant domain 1 or T cell receptor beta chain constant domain 2; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or cytokine inhibitor molecule; (iv) a death receptor signal enhancer; and/or (v) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Multifunctional molecules that bind to T cell related cancer cells and uses thereof

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Anti-TCR antibody molecules and uses thereof

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell

Provided herein are nucleic acid constructs, polypeptides and T cells related to antigen binding domains that bind to mutant calreticulin; and methods of use thereof for the treatment of diseases, including cancer.

Calreticulin binding constructs and engineered T cells for the treatment of diseases

Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin mutant protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or a modulator of a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Multifunctional molecules that bind to calreticulin and uses thereof

Multispecific molecules targeting tumor associated macrophages (TAMs) or myeloid derived suppressor cells (MDSCs) and methods of using the same, are disclosed.

Multispecific molecules and uses thereof

Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

Human mesothelin chimeric antigen receptors and uses thereof

The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a 'NKR-CAR' which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy

Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules

The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

Growing community of inventors

Cambridge, MA, United States of America

Andreas Loew